Is Healthy Life overvalued or undervalued?

As of 9 June 2025, Healthy Life's valuation grade has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE ratio of 48.20, an EV to EBITDA of 32.57, and a PEG ratio of 3.17, all significantly higher than typical industry benchmarks. In comparison to its peers, Healthy Life's PE ratio is lower than Hindustan Unilever's 53.96 and Nestle India's 75.24, but still places it in an expensive category within the FMCG sector. The company's recent stock performance has been volatile, with a notable 1-year return of 206.68%, which, while impressive, contrasts sharply with the Sensex's return of 7.50% over the same period. This suggests that despite the strong past performance, the current valuation may not be sustainable, reinforcing the conclusion that Healthy Life is overvalued.